The Intraarterial Route of Drug Delivery in the Chemotherapy of Malignant Brain Tumours

  • F. Loew
  • L. Papavero
Part of the Advances and Technical Standards in Neurosurgery book series (NEUROSURGERY, volume 16)


This review is based on literature data and own experiences in 79 patients with malignant brain tumours using intraarterial delivery of cytostatic agents as adjuvant therapy. A survey is given of the pharmacological rationale of this therapeutic approach, of the drugs which have been used and of the related experimental and clinical experiences. Advantages and limitations are discussed and clinical conclusion drawn.

Experience so far suggests that in anaplastic astrocytomas and oligodendrogliomas intraarterial ACNU might be as effective as intravenous BCNU against the tumours but causes less systemic side-effects.


Malignant Glioma Malignant Brain Tumour Cytostatic Agent Karnofsky Score Blood Tumour Barrier 

















distilled water








internal carotid artery




middle cerebral artery




median survival time


median time to tumour progression




molecular weight


octanol/water partition coefficient




quantitative autoradiography


ratio of drug delivery by arterial compared to venous infusion


relationship between the ratio of the pharmacological effects by arterial compared to venous infusion


somatosensory evoked potentials


transcranial doppler ultrasound


transient ischaemic attack








Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Blasberg RG, Groothuis D, Molnar P (1981) Application of quantitative autoradiographic measurements in experimental brain tumour models. Sem Neuro 1: 203–221CrossRefGoogle Scholar
  2. 2.
    Bonstelle CT, Kori SH, Rekate H (1983) Intracarotid chemotherapy of glioblastoma after induced blood-brain-barrier disruption. AJNR 4 (3): 810–812PubMedGoogle Scholar
  3. 3.
    Bremer AM, Nguyen TQ, Balsys R, Kleriga E (1982) Complications associated with intracarotid and intravertebral artery BCNU infusion for the treatment of patients with malignant brain tumour (Meeting Abstract). American Association of Neurological Surgeons, 234 ppGoogle Scholar
  4. 4.
    Bremer A, Kleriga E, Nguyen E, Gonzalez N, Balsys R (1984) Intracarotid BCNU in combination with systemic chemotherapy and adjuvant radiotherapy for malignant gliomas (Meeting Abstract). J Neurooncol 2 (3): 287Google Scholar
  5. 5.
    Bullard DE, Bigner SH, Bigner DD (1985) Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumour model. Cancer Res 45: 5240–5245PubMedGoogle Scholar
  6. 6.
    Calvo FA, Anton L, Pastor A, Dy C, Gil A, Harguindey SS, Sierrasesumaga L, Lage MM (1985) Intracarotid artery (ICA) cisplatinum (CDDP) and intravenous (IV) BCNU in the treatment of malignant glioma (Meeting Abstract). 3rd European Conference on Clinical Oncology and Cancer Nursing. June 16–20, 1985, Stockholm, Sweden, pp 150Google Scholar
  7. 7.
    De Wys WD, Fowler EH (1973) Report of vasculitis and blindness after intracarotid injection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC409962) in dogs. Cancer Chemother Rep 57: 33–40Google Scholar
  8. 8.
    Eckmann WW, Patlak CS, Fenstermacher JD (1974) A critical evaluation of the principle governing the advantages of intra-arterial infusions. J Pharmacokinet Biopharm 2: 257–285CrossRefGoogle Scholar
  9. 9.
    Fenstermacher JD, Cowles AL (1977) Theoretic limitations of intracarotid infusions in brain tumour chemotherapy. Cancer Treat Rep 61: 519–526PubMedGoogle Scholar
  10. 10.
    Fenstermacher JD, Gazendam J (1981) Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 65 [Suppl 2]: 27–37PubMedGoogle Scholar
  11. 11.
    Feun LG, Wallace S, Stewart DJ, Chuang VP, Yunk WK, Leavens ME, Burgess MA, Savaraj N et al (1984) Intracarotid infusion of Cis-Diamminedichloroplatinum in the treatment of recurrent malignant brain tumours. Cancer 54 (5): 794–799PubMedCrossRefGoogle Scholar
  12. 12.
    Feun LG, Martinez J, Lee YY, Yung WK, Charnsangavej C, Savaraj N, Wallace S (1986) Phase I and pharmacokinetic study of intracarotid (IC) Cisplatin and Bleomycin in malignant brain tumours (MBT) (Meeting Abstract). Proc Annu Meet Am Assoc Cancer Res 27: 189Google Scholar
  13. 13.
    Feun LG, Lee YY, Yung WK, Charnsangavej C, Savaraj N, Tang RA, Wallace S (1986) Phase II trial of intracarotid BCNU and Cisplatin in primary malignant brain tumours. Cancer Drug Deliv 3 (2): 147–156PubMedCrossRefGoogle Scholar
  14. 14.
    Feun LG, Lee YY, Yung WK, Savaraj N, Wallace S (1987) Intracarotid VP— 16 in malignant brain tumours. Neurooncol 4 (4): 397–401CrossRefGoogle Scholar
  15. 15.
    Gebarski, Greenberg HS, Gabrielsen TO, Vine AK (1984) Orbital angiographic changes after intracarotid BCNU chemotherapy. AJNR 5 (1): 55–58PubMedGoogle Scholar
  16. 16.
    Greenberg HS, Ensminger WD, Seeger JF, Kindt G, Dakhil S, Doan K (1980) Escalating doses of intracarotid bischloroethylnitrosourea (BCNU) for malignant gliomas (Meeting Abstract). Clin Res 28 (4): 743AGoogle Scholar
  17. 17.
    Greenberg HS, Ensminger W, Layton P, Gebarski S, Meyer MB, Bender J, Grillo-Lopez A (1984) A phase 1–2 evaluation of intra-arterial diazoquone (AZQ) for malignant tumours of the central nervous system (Meeting Abstract). Proc Annu Meet Am Soc Clin Oncol 3: 256Google Scholar
  18. 18.
    Greenberg HS, Ensminger WD, Chandler WF, Layton PB, Junck L, Knake J, Vine AK (1984) Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg 61 (3): 423–429PubMedCrossRefGoogle Scholar
  19. 19.
    Grimson BS, Mahaley MS Jr, Dubey HD (1981) Ophthalmic and central nervous system complications following intracarotid BCNU (carmustine). J Clin Neuroophthalmol 1: 261–264PubMedCrossRefGoogle Scholar
  20. 20.
    Groothuis DR, Blasberg RG (1985) Rational brain tumour chemotherapy: The interaction of drug and tumour. Neurologic Clinics 3: No 4, pp 801PubMedGoogle Scholar
  21. 21.
    Harper GR, Blasberg RG, Fenstermacher JD, Patlak CS (1983) Illustration of the intra-arterial (IA) chemotherapy delivery advantage following intra-carotid administration of radio-labeled 2-deoxy-D-glucose. Proc Am Assoc Cancer Res 24: 1080Google Scholar
  22. 22.
    Hidalgo V, Dy C, Fernandez Hidalgo O, Calvo FA (1987) Simultaneous radiotherapy and cis-platinum for the treatment of brain metastases. A pilot study. Am J Clin Oncol 10 (3): 205–209PubMedCrossRefGoogle Scholar
  23. 23.
    Hiesiger EM, Voorhies R, Basler GA (1984) Comparison of 14 C-methotrexate (14 C-MTX) delivery by intravenous vs intracarotid (IC) route without or with IC mannitol in experimental rat brain tumours as measured by quantitative autoradiography (QAR). Proc Am Assoc Cancer 25: 363Google Scholar
  24. 24.
    Hochberg FH, Parker LM, Takvorian T (1981) High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54: 455–460PubMedCrossRefGoogle Scholar
  25. 25.
    Hochberg FH, Pruitt AA, Beck DO, DeBrun G, Davis K (1985) The rationale and methodology for intra-arterial chemotherapy with BCNU as treatment for glioblastoma. J Neurosurg 63 (6): 876–880PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson WD, Parkinson D, Wolpert SM, Kasdon DL, Kwan ES, Laucella M, Anderson ML (1987) Intracarotid chemotherapy with l,3-bis-(2-chlorethyl)-l-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma. Neurosurgery 20 (4): 577–580PubMedCrossRefGoogle Scholar
  27. 27.
    Kapp J, Vance R, Parker JL, Smith RR, Mahaley MS, Neuwelt EA (1982) Limitations of high-dose intra-arterial 1,3-bis-(2-chlorethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas. Neurosurgery 10 (6): 715–719PubMedCrossRefGoogle Scholar
  28. 28.
    Kapp JP, Ross RI, Tucker EM (1983) Supraophthalmic carotid infusion for brain-tumour chemotherapy. Technical note. J Neurosurg 58(4): 616–618PubMedCrossRefGoogle Scholar
  29. 29.
    Kapp JP, Vance R (1984) Supraophthalmic carotid infusion for recurrent glioma. Rationale, technique and preliminary results for cisplatinum and BCNU (Meeting Abstract). J Neurooncol 2 (3): 290Google Scholar
  30. 30.
    Kleinschmidt-De Masters BK (1986) Intracarotid BCNU leukoencephalopathy. Cancer 57: 1276–1280CrossRefGoogle Scholar
  31. 31.
    Kuruvilla A, Groothuis D (1985) Predicting the rate of transcapillary transport of drugs in brain tumours: role of lipid solubility and molecular weight. Neurology 35 [Suppl 1]: 289Google Scholar
  32. 32.
    Layton B, Greenberg HS, Stetson PL, Ensminger WD, Gywes JW (1984) BCNU solubility and toxicity in the treatment of malignant astrocytomas. J Neurosurg 60: 1134–1137PubMedCrossRefGoogle Scholar
  33. 33.
    Lehane D, Moiel R, Bryan N, Porowitz B, Kapp J, Eyre H, Rudolph L (1984) Adjuvant therapy for malignant gliomas (MG) using intra-arterial (IA) cis-platinum (CP) radiation therapy (RT) and CCNU (Meeting Abstract). Fourth International Conference on the Adjuvant Therapy of Cancer, 21–24 March 1984, Tucson, AZ, p 41Google Scholar
  34. 34.
    Levin VA, Shapiro WR, Clancy TP (1970) The uptake, distribution and antitumour activity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the murine glioma. Cancer Res 30: 2451–2455PubMedGoogle Scholar
  35. 35.
    Levin VA, Kabra PM (1975) Brain and tumour pharmacokinetics of BCNU and CCNU following IV and intracarotid artery (ICA) administration. Proc Am Assoc Cancer Res 16: 19Google Scholar
  36. 36.
    Levin VA, Kabra PM, Freeman-Dove MA (1978) Pharmacokinetics of intracarotid artery 14 C-BCNU in the squirrel monkey. J Neurosurg 48: 587–593PubMedCrossRefGoogle Scholar
  37. 37.
    Levy G, Gibaldi M (1972) Pharmacokinetics of drug action. Ann Rev Pharm 12: 85–98CrossRefGoogle Scholar
  38. 38.
    Lutz RJ, Dedrick RL, Boretos JW, Oldfield EH, Blacklock JB, Doppman JL (1986) Mixing studies during intracarotid infusions in an in vitro model. J Neurosurg 64: 277–283PubMedCrossRefGoogle Scholar
  39. 39.
    Mahaley MS, Whaley RA, Blue M, Bertsch L (1986) Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas. J Neurooncol 3: 297–314PubMedCrossRefGoogle Scholar
  40. 40.
    Mani RL, Eisenberg RL, Mc Donald EJ Jr et al (1978) Complications of catheter cerebral arteriography: analysis of 5,000 procedures. I. Criteria and incidence. AJR 131: 861–865PubMedGoogle Scholar
  41. 41.
    Mergelsberg M, Musch E (1987) Real-time ultrasonically guided catheterization of the internal jugular vein. Tumor Diagnostik & Therapie 4: 164–166Google Scholar
  42. 42.
    Miyagami M, Kagawa Y, Tsubokawa T (1985) ACNU delivery to malignant glioma tissue by osmotic blood brain barrier modification with intracarotid infusion of hyperosmolar mannitol. No Shinkei Geka 13 (9): 955–963PubMedGoogle Scholar
  43. 43.
    Neuwelt EA, Diehl JT, Vu LH (1981) Monitoring of methotrexate delivery in patients with malignant brain tumours after osmotic blood-brain-barrier disruption. Ann Inter Med 94: 449–454Google Scholar
  44. 44.
    Nomura K, Watanabe T, Nakamura O, Ohira M, Shibui S, Takakura K, Miki Y (1984) Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas. Neurosurg Rev 7: 13–22PubMedCrossRefGoogle Scholar
  45. 45.
    Oldfield EH, Dedrick RL, Yeager RL, Clark WC, De Vroom HL, Chatterji DC, Doppman JL (1985) Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage. J Neurosurg 63 (5): 726–732PubMedCrossRefGoogle Scholar
  46. 46.
    Oldfield EH, Clark WC, Dedrick RL, Egorin MJ, Austin HA, De Vroom HL, Joyce KM, Doppman JL (1987) Reduced systemic drug exposure by combining intraarterial cis — diammine-dichloroplatinum (II) with haemodialysis of regional venous drainage. Cancer Res 47 (7): 1962–1967PubMedGoogle Scholar
  47. 47.
    Omojola MF, Fox AJ, Auer RN (1982) Haemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs. J Neurosurg 57: 791–796PubMedCrossRefGoogle Scholar
  48. 48.
    Papavero L, Loew F, Jaksche H (1987) Intracarotid infusions of ACNU and BCNU as adjuvant therapy of malignant gliomas. Acta Neurochir (Wien) 85: 128–137CrossRefGoogle Scholar
  49. 49.
    Papavero L, Schwerdtfeger K, Vaterrodt TH, Jaksche H, Loew F (1987) Neuromonitoring (EEG, SSEP and TCD) during intracarotid infusions of ACNU in patients with anaplastic gliomas. J Electroencephal Clin Neurophysiol (in press)Google Scholar
  50. 50.
    Papavero L, Roosen N, Kiwit JWC, Jaksche H, Schirmer M, Lins E, Bock WJ, Loew F (1987) The role of regional chemotherapy with ACNU in the treatment of anaplastic gliomas. III ICRCT Ulm, Kreidler et al (eds) Karger (in press)Google Scholar
  51. 51.
    Phillips TW, Chandler EF, Kindt GW, Ensminger WD, Greenberg HS, Seeger JF, Doan KM, Gywes JW, Neuwelt EA (1982) New implantable continuous-administration and bolus-dose intracarotid drug delivery system for the treatment of malignant gliomas. Neurosurgery 11 (2): 213–218PubMedCrossRefGoogle Scholar
  52. 52.
    Ross L, Kapp JP, Hochberg F (1983) Solvent systems for intracarotid 1,3bis(2-chloroethyl)-2-nitrosourea (BCNU) infusion. Neurosurgery 12: 512–514PubMedCrossRefGoogle Scholar
  53. 53.
    Saris SC, Shook DR, Blasberg RG, Dedrick RL, Doppman JL, Bankievicz KS, Blacklock BJ, Oldfield EH (1987) Carotid artery mixing with diastole-phased pulsed drug infusion. J Neurosurg 67: 721–725PubMedCrossRefGoogle Scholar
  54. 54.
    Safdari H, Mompeon B, Dubois JB, Gros C (1985) Intraarterial 1,3-bis(2chloroethyl)- 1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: A preliminary report. Surg Neurol 24 (5): 490–497PubMedCrossRefGoogle Scholar
  55. 55.
    Shapiro WR, Voorhies RM, Basler GA, Blasberg RG, Posner JB (1982) Regional methotrexate entry into experimental rat brain tumours as measured by quantitative autoradiography (QAR). Neurology 32 (2), April 1982Google Scholar
  56. 56.
    Shapiro WR, Green SB (1987) Reevaluating the efficacy of intraarterial BCNU (letter). J Neurosurg 66: 313–315PubMedGoogle Scholar
  57. 57.
    Shibui S, Watanabe T, Miki Y (1983) High dose chemotherapy with autologous bone marrow transplantation for malignant brain tumours. Neurol Surg 11: 73–729Google Scholar
  58. 58.
    Shingleton J, Bienfang DC, Albert DM, Ensminger WD, Chandler WF, Greenberg HS (1982) Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 100 (11): 1766–1772PubMedGoogle Scholar
  59. 59.
    Spitzer G, Dicke KA, Verma (1979) High-dose BCNU therapy with autologous bone marrow infusion: Preliminary observations. Cancer Treat Rep 63: 1257–1264PubMedGoogle Scholar
  60. 60.
    Stewart PA, Hayakawa K, Farrel CL, Del Maestro RF (1987) Quantitative study of microvessel ultrastructure in human peritumoural brain tissue. J Neurosurg 67: 697–705PubMedCrossRefGoogle Scholar
  61. 61.
    Stewart DJ, Wallace S, Feun L, Leavens M, Young SE, Handel S, Mavligit G, Benjamin RS (1982) A phase I study of intracarotid infusion of cis-diamminedichloroplatinum (II) in patients with recurrent malignant intracerebral tumours. Cancer Res 42 (5): 2059–2062PubMedGoogle Scholar
  62. 62.
    Stewart DJ, O’Bryan RM, Al Saraf M (1983) Intraarterial Cis-platinum chemotherapy for patients with primary and metastatic brain tumours. Cancer Drug Deliv 1 (1): 69–77CrossRefGoogle Scholar
  63. 63.
    Thomas DGT, Darling JL, Paul EA, Mott TJ, Godlee JN, Tobias JS, Capra LG, Collins CD, Mooney C, Bozek T, Finn GP, Arigbabu SO, Bullard DE, Shannon N, Freshney RY (1985) Assay of anti-cancer drugs in tissue culture: Relationship of Relapse Free Interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. Br J Cancer 51: 525–532PubMedCrossRefGoogle Scholar
  64. 64.
    Tyler JL, Yamamoto L, Diksic M, Sheron J, Villemure JG, Worthington C, Evans AC, Feinel W (1986) Pharmacokinetics of superselective intra-arterial and intravenous 11 C-BCNU evaluated by PET. J Nucl Med 27: 775–780PubMedGoogle Scholar
  65. 65.
    Vance RB, Kapp JP (1986) Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma. J Neurooncol 3 (4): 287–290PubMedCrossRefGoogle Scholar
  66. 66.
    Warnke PC, Kuruvilla A, Mikhael M, Groothuis D (1985) The effect of hyperosmotic blood-brain-barrier disruption on capillary permeability in normal and tumour bearing dogs. Neurology 35 [Suppl 1]: 289Google Scholar
  67. 67.
    Warnke PC, Blasberg RG, Groothuis DR (1987) The effect of hyperosmotic blood-brain-barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann Neurol 22 (3): 300–305PubMedCrossRefGoogle Scholar
  68. 68.
    West CR, Avellanosa AM, Barua NR, Patel A (1980) Phase II study on malignant gliomas of the brain treated with intra-arterial BCNU in combination with vincristine and procarbazine (Meeting Abstract). Proc Am Assoc Cancer Res 21: 482Google Scholar
  69. 69.
    Yamashita J, Handa AH, Tokuriki Y (1983) Intra-arterial ACNU therapy for malignant brain tumours. J Neurosurg 59: 424–430PubMedCrossRefGoogle Scholar
  70. 70.
    Yumitori K, Handa H, Teraura T, Yamashita J (1984) Treatment of malignant brain tumours with ACNU and phenobarbital: continuous infusion of ACNU into internal carotid artery and systemic administration of phenobarbital. Acta Neurochir (Wien) 70: 155–168CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1988

Authors and Affiliations

  • F. Loew
    • 1
  • L. Papavero
    • 1
  1. 1.Neurosurgical ClinicSaarland University Medical School Homburg/SaarGermany

Personalised recommendations